Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure

The role of ribavirin (RBV) in the era of direct-acting antivirals (DAA) is not clear, and DAA studies have been largely genotype- and regimen-specific. Using data from the Chronic Hepatitis Cohort Study, we evaluated the role of RBV and increased DAA treatment duration among patients with chronic h...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Viral Hepat
Hauptverfasser: Lu, Mei, Wu, Kuan-Han, Li, Jia, Moorman, Anne C., Spradling, Philip R., Teshale, Eyasu H., Boscarino, Joseph A., Daida, Yihe G., Schmidt, Mark A., Rupp, Loralee B., Zhang, Talan, Trudeau, Sheri, Gordon, Stuart C.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2019
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6764853/
https://ncbi.nlm.nih.gov/pubmed/31197910
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jvh.13162
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge